可每12周一次!信达生物双靶点新药2期临床完整数据公布

医药时间
06 May

5月6日,信达生物宣布,在2025年视觉和眼科研究协会(ARVO)年会上以口头报告的形式公布了其研发的重组人血管内皮生长因子受体(VEGFR)和人补体受体1(CR1)融合蛋白依莫芙普注射液(研发代号:IBI302)在新生血管性年龄相关性黄斑变性(nAMD)受试者中为期一年的临床2期研究结果。ARVO年会于5月4~8日在美国犹他州盐湖城举办,是全球最大的眼科与视觉研究盛会之一。依莫芙普是一种双特异性...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10